The table below shows the top 15 BSE Healthcare Index stocks by their highest market cap.
| Name | Market Cap ( Cr ) | Close Price |
| Sun Pharmaceutical Industries Ltd | 377703.31 | 1574.20 |
| Cipla Ltd | 118961.26 | 1473.45 |
| Dr Reddy’s Laboratories Ltd | 104960.73 | 6303.30 |
| Zydus Lifesciences Ltd | 96538.97 | 953.75 |
| Divi’s Laboratories Ltd | 92501.20 | 3484.45 |
| Torrent Pharmaceuticals Ltd | 90092.48 | 2661.95 |
| Apollo Hospitals Enterprise Ltd | 87149.32 | 6061.10 |
| Mankind Pharma Ltd | 86549.14 | 2160.55 |
| Lupin Ltd | 76488.36 | 1678.75 |
| Max Healthcare Institute Ltd | 70935.95 | 729.90 |
| Aurobindo Pharma Ltd | 63506.96 | 1083.85 |
| Alkem Laboratories Ltd | 60982.33 | 5100.35 |
| Abbott India Ltd | 58160.30 | 27370.45 |
| GlaxoSmithKline Pharmaceuticals Ltd | 36091.96 | 2130.50 |
| Biocon Ltd | 33498.55 | 279.95 |
Content:
Stocks in BSE Healthcare Index
Sun Pharmaceutical Industries Ltd
The Market Cap of Sun Pharmaceutical Industries Ltd is ₹377,703.31. The one-month return percentage is 8.90%. The one-year return percentage is 63.09%. The stock is 0.86% away from its 52 week high.
Sun Pharmaceutical Industries Limited, headquartered in India, specializes in producing generic pharmaceuticals.
The company is involved in manufacturing, developing, and promoting a broad array of branded and generic formulations and active pharmaceutical ingredients (APIs). Sun Pharma offers a diverse portfolio of medicines with a focus on chronic and acute treatments. I
Cipla Ltd
The Market Cap of Cipla Ltd is ₹118,961.26. The one-month return percentage is 4.80%. The one-year return percentage is 67.27%. The stock is 1.48% away from its 52 week high.
Cipla Limited, an Indian-based company, primarily focuses on pharmaceuticals. It operates through two main segments: Pharmaceuticals and New Ventures.
The Pharmaceuticals segment involves the development, manufacturing, selling, and distribution of generic or branded generic medicines and Active Pharmaceutical Ingredients (API). The New Ventures segment encompasses consumer healthcare, Biosimilars, and specialty business operations.
Dr Reddy’s Laboratories Ltd
The Market Cap of Dr Reddy’s Laboratories Ltd is ₹104,960.73. The one-month return percentage is 4.92%. The one-year return percentage is 41.99%.The stock is 3.21% away from its 52 week high.
Dr. Reddy’s Laboratories Limited, headquartered in India, operates as a prominent global pharmaceutical entity. Its diverse offerings encompass active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) medications.
The company focuses on several key therapeutic areas, including gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s Laboratories is structured into segments: Pharmaceutical Services and Active Ingredients, Global Generics, and Others.
Zydus Lifesciences Ltd
The Market Cap of Zydus Lifesciences Ltd is ₹96,538.97. The one-month return percentage is 24.36%. The one-year return percentage is 100.30%. The stock is 0.30% away from its 52 week high.
Zydus Lifesciences Ltd., an India-based company in the field of life sciences, focuses on various activities including research, development, manufacturing, marketing, and sales of a range of products.
These encompass finished dosage human formulations like generics and specialty formulations, which include biosimilars and vaccines, as well as active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness items. Notable offerings from the company include Bilypsa for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Oxemia for the treatment of anemia in chronic kidney disease (CKD) patients, Ujvira as a biosimilar to Kadcyla, and Exemptia.
Divi’s Laboratories Ltd
The Market Cap of Divi’s Laboratories Ltd stands at ₹92,501.20. Over the past month, the return percentage has been -5.09%. Looking back over the year, the return percentage stands at 22.40%.The stock is 16.93% away from its 52 week high.
Divi’s Laboratories Limited, an Indian company, specializes in the manufacturing and distribution of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients, primarily focusing on exports.
Its product portfolio encompasses a range of substances such as Bupropion HCl, Capecitabine, Carbidopa, and many others. Besides its generic offerings, the company also provides custom synthesis services to support pharmaceutical companies in various stages, from clinical trials to product launch and late-stage lifecycle management of patented products.
Torrent Pharmaceuticals Ltd
The Market Cap of Torrent Pharmaceuticals Ltd is ₹90,092.48. Over the past month, the return percentage has been 4.43%. Looking back over the year, the return percentage stands at 77.17%. The stock is 2.67% away from its 52 week high.
Torrent Pharmaceuticals Limited, headquartered in India, specializes in a range of therapeutic segments including cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology.
The company is actively involved in the research, development, manufacturing, marketing, and global distribution of both branded and generic pharmaceutical formulations. Among its notable pediatric products are Tedibar, Atogla, Spoo, and B4 Nappi, while its acne and face care lines feature brands like Clinmiskin, ACNEMOIST, TRACNILO, and fash.
Apollo Hospitals Enterprise Ltd
The Market Cap of Apollo Hospitals Enterprise Ltd stands at ₹87,149.32. Over the past month, the return percentage has been -4.24%. Over the course of the last year, the return percentage is 37.09%. The stock is 13.42% away from its 52 week high.
Apollo Hospitals Enterprise Limited, an India-based integrated healthcare firm, operates a diverse range of services encompassing hospital care, pharmaceutical sales, and wellness products.
Its operations span private hospitals, clinics, diagnostic centers, and pharmacies. The company’s business segments are healthcare services, retail health and diagnostics, digital health, and pharmacy distribution, among others. Its focus lies in hospital services and related offerings, including retail healthcare services such as clinics and diagnostics.
Mankind Pharma Ltd
The Market Cap of Mankind Pharma Ltd is ₹86,549.14. Over the past month, the return percentage has been 4.06%. Looking back over the year, the return percentage stands at 51.91%.The stock is 6.33% away from its 52 week high.
Mankind Pharma Limited, headquartered in India, specializes in the development, production, and promotion of a wide array of pharmaceutical formulations spanning diverse acute and chronic therapeutic fields, along with various consumer healthcare offerings.
Its extensive portfolio covers numerous therapeutic segments such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain management, among others.
Lupin Ltd
The Market Cap of Lupin Ltd stands at ₹76,488.36. Over the past month, the return percentage has been 11.12%. Over the course of the last year, the return percentage is 153.42%. The stock is 1.27% away from its 52 week high.
Lupin Limited, headquartered in India, specializes in the production, development, and global marketing of a diverse array of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
With a presence in various therapeutic segments such as Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives, and Nonsteroidal Anti-Inflammatory Drugs, the company also operates in the Anti-TB and Cephalosporins sectors.
Max Healthcare Institute Ltd
The Market Cap of Max Healthcare Institute Ltd is ₹70,935.95. Over the past month, the return percentage has been -3.87%. Looking back over the year, the return percentage stands at 69.43%. The stock is 24.67% away from its 52 week high.
Max Healthcare Institute Limited, headquartered in India, is a leading player in the Medical and Healthcare Services sector.
In addition to its core hospital operations, it oversees Max@Home, a homecare division, and Max Lab, a pathology unit. Max@Home provides a suite of health and wellness services within the comfort of individuals’ homes, while Max Lab extends pathology services beyond the hospital network.
BSE Healthcare Stocks – FAQ
What Are The Best Stocks In BSE Healthcare?
These are the top 5 companies in BSE Healthcare based on market capitalization:
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
- Dr Reddy’s Laboratories Ltd
- Zydus Lifesciences Ltd
- Divi’s Laboratories Ltd
Which BSE Healthcare Stock Has the Highest Weightage?
These are the top 5 stocks in BSE Healthcare Stock based on points contribution: Fortis Healthcare Ltd, Divi’s Laboratories Ltd, Laurus Labs Ltd, Glenmark Pharmaceuticals Ltd, and Zydus Lifesciences Ltd.
How many stocks are there in the BSE Healthcare Index?
The BSE Healthcare Index comprises around 80+ stocks representing various companies within the healthcare sector, including pharmaceuticals, biotechnology, hospitals, and other related industries.
Can I Invest In BSE Healthcare Stocks?
Yes, you can invest in BSE Healthcare stocks through various avenues such as direct stock purchases, mutual funds, or exchange-traded funds (ETFs) that track the performance of the BSE Healthcare Index.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
